Glomerular disease: Lupus nephritis trials end in disappointment

Nature Reviews Nephrology

Volumn 5, Issue 6, 2009, Pages 303-

  Harman, Chloë ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; ATACICEPT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; RITUXIMAB; STEROID;

ARTICLE; B LYMPHOCYTE; CELL THERAPY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INFECTION; INFERTILITY; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL RESEARCH; METABOLIC DISORDER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEINURIA; RHEUMATOID ARTHRITIS;

EID: 70350153802     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.64     Document Type: Article

References (2)

1. Genentech. Phase III study of Rituxan in lupus nephritis did not meet primary end point [online], http://wwW.genE.com/gene/news/press-releases/ display.do?method=detail&id=11947 (2009).
2. Biomarin. results of first interim efficacy analysis for Riquent Phase III asPEN trial: Continuation of the trial is futile [online], http://phx.corporate-iR.net/phoenix.zhtml?c=106657&p=irol- newsArticle&ID=1255856&highlight (2009).